A U.S. study suggests people with type 2 diabetes might soon be able to control both their glucose and cholesterol levels with a single drug.
Researchers led by Professor Vivian Fonseca at Tulane University conducted a clinical trial that demonstrated the compound colesevelam HCl, in combination with Sulfonylurea-based therapy in patients with inadequately controlled type 2 diabetes, achieved significantly reduced glucose levels versus those in the study taking a placebo.
"People with uncontrolled type 2 diabetes and high cholesterol face a number of challenges in keeping their glucose levels and cholesterol in check," said Fonseca. "This study demonstrated the potential to improve two important metabolic parameters with one drug."
Patients who received colesevelam HCl were shown to have significant reductions in blood sugar levels, and participants' lipid profiles in the colesevelam HCl group also showed substantial improvement over placebo.
An application for the commercial production and sale of the drug is pending with the U.S. Food and Drug Administration. (c) UPI
一项美国的研究表明，II型糖尿病患者将很快通过使用一种药物控制血糖和胆固醇水平。
Tulane大学Vivian Fonseca教授领导的研究小组通过临床试验发现，相对于安慰剂组，使用化合物colesevelam HCl，同时采用基于磺酰脲类药物治疗的II型糖尿病患者，血糖水平明显降低。
Fonseca说，II型糖尿病患者和高胆固醇血症患者在控制血糖和胆固醇中面临很多问题，这项研究将有可能通过一种药物改善两种重要的代谢因素。
使用colesevelam HCl的患者，血糖水平明显降低。而且脂质曲线相对于对照组有实质性改善。
这种药物的商业化生产和销售的申请，正接受美国食品和药物管理局的审批。
|
